Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: Results of a randomized, long-term extension trial (RESTORE2)

British Journal of Dermatology

Volumn 168, Issue 6, 2013, Pages 1325-1334

  Reich, K ^a   Wozel, G ^b   Zheng, H ^c   Van Hoogstraten, H J F ^c   Flint, L ^c   Barker, J ^d  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ABSCESS; ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HUMAN; INFLUENZA; INFUSION RELATED REACTION; JAW ABSCESS; LUNG TUBERCULOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TONSILLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878666302     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12404     Document Type: Article

References (18)

1. Sivamani RK, Goodarzi H, Garcia MS, et al,. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 2013; 44: 121-40.
2. Chaudhari U, Romano P, Mulcahy LD, et al,. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001; 357: 1842-7.
3. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
4. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
5. Schering-Plough, Ltd (Merck Sharp & Dohme Limited). Remicade (infliximab) summary of product characteristics. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/ 000240/WC500050888.pdf (last accessed 24 April 2013).
6. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-15.
7. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
8. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
9. Lee LY, Sanderson JD, Irving PM,. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24: 1078-85.
10. Steenholdt C, Svenson M, Bendtzen K, et al,. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 51-8.
11. Lichtenstein GR, Diamond RH, Wagner CL, et al,. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
12. Maini RN, Breedveld FC, Kalden JR, et al,. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
13. Wee JS, Petrof G, Jackson K, et al,. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol 2012; 167: 411-16.
14. Maini R, St Clair EW, Breedveld F, et al,. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
15. Lipsky PE, van der Heijde DM, St Clair EW, et al,. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
16. St Clair EW, van der Heijde DM, Smolen JS, et al,. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
18. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.